# NDUFA1 Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- The *NDUFA1* gene encodes a critical accessory subunit of mitochondrial Complex I, essential for its assembly and catalytic activity in oxidative phosphorylation. Pathogenic variants lead to mitochondrial complex I deficiency, presenting as severe multisystem disorders like Leigh syndrome and fatal infantile lactic acidosis.
- NDUFA1 is a small, hydrophobic transmembrane protein with a conserved N-terminal "MWFE" motif crucial for its interaction with assembly factors like TMEM126B, facilitating the early stages of Complex I membrane arm assembly.
- Beyond its role in ATP production, NDUFA1 indirectly influences reactive oxygen species (ROS) homeostasis and apoptosis regulation by maintaining Complex I structural integrity; destabilization due to mutations increases oxidative stress and can sensitize cells to programmed cell death.
- *NDUFA1* mutations follow an X-linked inheritance pattern, with males typically more severely affected, and differential diagnosis requires biochemical assessment of Complex I activity and comprehensive genetic testing due to overlapping phenotypes with other mitochondrial disorders.
- Emerging evidence implicates NDUFA1 and Complex I in cancer biology, particularly in OXPHOS-dependent cancers like AML, positioning it as a potential therapeutic target for novel anti-cancer strategies, alongside investigational treatments for mitochondrial diseases such as riboflavin and CoQ10 supplementation.

---

## Executive Summary & Key Metadata

The *NDUFA1* gene encodes the NADH:ubiquinone oxidoreductase subunit A1, a critical accessory subunit of mitochondrial Complex I (CI), the first and largest enzyme of the oxidative phosphorylation (OXPHOS) system. This integral membrane protein, also known as MWFE, is indispensable for the assembly and catalytic activity of Complex I. Pathogenic variants in *NDUFA1* are a recognized cause of mitochondrial complex I deficiency, a severe multisystem disorder with a broad phenotypic spectrum ranging from Leigh syndrome to fatal infantile lactic acidosis. Beyond its canonical role in cellular respiration, emerging evidence implicates NDUFA1 in reactive oxygen species (ROS) homeostasis, apoptosis regulation, and cancer biology, positioning it as a potential therapeutic target.

| **Attribute** | **Detail** |
| :--- | :--- |
| **HGNC Symbol** | NDUFA1 |
| **UniProt Accession** | O15239 |
| **Representative PDB ID** | 5XTD (Bovine Complex I), 6ZR2 (Ovine Complex I), 7TZ1 (Human Complex I) |
| **Chromosomal Locus** | Xq24 |
| **Primary Molecular Function** | Accessory subunit of mitochondrial NADH:ubiquinone oxidoreductase (Complex I); required for complex assembly and enzymatic activity |
| **Disease & Pathology Associations** | Mitochondrial complex I deficiency, nuclear type 12 (MC1DN12); Leigh syndrome; fatal infantile lactic acidosis; cardiomyopathy; encephalopathy |
| **Gene Type** | Protein-coding |
| **Expression** | Ubiquitous, highest in tissues with high energy demand (heart, skeletal muscle, brain, kidney) |

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Localization and Coordinates

The *NDUFA1* gene is located on the long (q) arm of the X chromosome at cytogenetic band Xq24. The reference genome assembly (GRCh38/hg38) places the gene between base pairs 119,559,912 and 119,565,591 on the forward strand (NCBI Reference Sequence: NC_000023.11). The gene spans approximately 5.7 kilobases (kb) of genomic DNA.

### 1.2 Gene Structure and Promoter Architecture

*NDUFA1* has a relatively simple genomic structure, comprising three exons and two introns. The canonical transcript (NM_004541.5) is 1,047 nucleotides long and encodes a 70-amino acid precursor protein. The mature protein, after cleavage of the mitochondrial targeting sequence (MTS), is 58 amino acids in length.

The promoter region of *NDUFA1* lacks a canonical TATA box, a feature common to many housekeeping genes. Instead, it contains a GC-rich region with multiple putative Sp1 (Specificity Protein 1) transcription factor binding sites. These Sp1 sites are critical for basal transcriptional activity. Additionally, the promoter contains consensus binding motifs for NRF-1 (Nuclear Respiratory Factor 1) and NRF-2 (also known as GA-binding protein, GABP), which are master regulators of nuclear-encoded mitochondrial genes. NRF-1 and NRF-2 coordinate the expression of *NDUFA1* with other OXPHOS subunits in response to cellular energy demands and mitochondrial biogenesis signals, often acting in concert with the transcriptional co-activator PGC-1α (Peroxisome proliferator-activated receptor gamma coactivator 1-alpha).

### 1.3 Enhancer Elements and Epigenetic Regulation

Chromatin immunoprecipitation sequencing (ChIP-seq) data from the ENCODE project and the FANTOM5 consortium indicate the presence of active enhancer elements in the first intron of *NDUFA1*. These regions are marked by histone modifications such as H3K27ac (acetylation of lysine 27 on histone H3) and H3K4me1 (monomethylation of lysine 4 on histone H3), which are hallmarks of active enhancers. The intronic enhancer is predicted to interact with the promoter via chromatin looping, facilitating robust and tissue-specific expression. DNA methylation analysis of the CpG islands within the promoter region suggests that methylation status can modulate *NDUFA1* expression, with hypermethylation associated with transcriptional silencing in certain pathological contexts, including some cancers.

### 1.4 Alternative Splicing and Isoforms

The primary transcript of *NDUFA1* undergoes alternative splicing, producing two main transcript variants:

1.  **Transcript Variant 1 (NM_004541.5):** This is the canonical, protein-coding transcript. It includes all three exons and encodes the functional 70-amino acid precursor protein. This is the dominant isoform expressed in all tissues.
2.  **Transcript Variant 2 (NR_033395.2):** This variant is a non-coding RNA. It arises from alternative splicing that retains intron 2, introducing a premature stop codon. This transcript is predicted to be a target for nonsense-mediated mRNA decay (NMD) and may play a regulatory role in fine-tuning NDUFA1 protein levels, although its physiological significance is not fully characterized.

No other significant protein-coding isoforms have been validated experimentally. The lack of isoform diversity underscores the critical, non-redundant function of the canonical NDUFA1 protein.

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Primary Structure and Mitochondrial Targeting

The NDUFA1 precursor protein is synthesized in the cytosol as a 70-amino acid polypeptide. The N-terminal 12 amino acids constitute a cleavable mitochondrial targeting sequence (MTS), which is rich in basic and hydroxylated residues, forming an amphipathic α-helix. This helix is recognized by the translocase of the outer mitochondrial membrane (TOM) complex and the translocase of the inner mitochondrial membrane (TIM23) complex, facilitating the import of the protein into the mitochondrial matrix. Upon import, the MTS is proteolytically cleaved by the mitochondrial processing peptidase (MPP), yielding the mature 58-amino acid protein (MWFE motif).

### 2.2 Secondary and Tertiary Structure

The mature NDUFA1 protein is a small, highly hydrophobic transmembrane protein. Its structure is characterized by a single, well-defined transmembrane α-helix spanning residues 14–38 of the mature protein. This helix is flanked by short hydrophilic N-terminal (residues 1–13) and C-terminal (residues 39–58) domains that face the mitochondrial matrix.

The amino acid sequence of the transmembrane domain is highly conserved across species, from yeast to humans, highlighting its functional importance. The N-terminal matrix-exposed domain contains the characteristic "MWFE" motif (Methionine-Tryptophan-Phenylalanine-Glutamate) at positions 1–4 of the mature protein, which gives the protein its alternative name. This motif is critical for the chaperone-mediated assembly of Complex I.

### 2.3 Quaternary Structure and Position within Complex I

NDUFA1 is not a catalytic subunit. Instead, it is a structural and assembly factor that resides within the membrane arm of Complex I. High-resolution cryo-electron microscopy (cryo-EM) structures of mammalian Complex I (e.g., bovine PDB: 5XTD, ovine PDB: 6ZR2, and human PDB: 7TZ1) have resolved the precise position of NDUFA1. It is located at the interface between the Q-module (the ubiquinone-binding module) and the proximal proton-pumping module (PPb) of the membrane arm.

NDUFA1 is situated in close proximity to other accessory subunits, including NDUFA2, NDUFA6, NDUFA8, NDUFA9, and NDUFA13. It forms extensive hydrophobic interactions with the transmembrane helices of these neighboring subunits, as well as with the ND1 and ND2 (MT-ND1, MT-ND2) mitochondrial-encoded core subunits. This intricate network of interactions is essential for stabilizing the architecture of the membrane arm and for creating a structural platform for the correct assembly and function of the proton-pumping machinery.

### 2.4 Structural Role in Complex I Assembly

The "MWFE" motif at the N-terminus of NDUFA1 is a key interaction site for the assembly factor TMEM126B. TMEM126B is a component of the mitochondrial complex I assembly (MCIA) complex, which also includes the proteins NDUFAF1 (CIA30), ECSIT, ACAD9, and COA1. The interaction between NDUFA1 and TMEM126B is a critical early step in the assembly of the membrane arm of Complex I. Specifically, NDUFA1 is one of the first accessory subunits to be incorporated into the ND2-containing assembly intermediate. This interaction stabilizes the nascent ND2 module, preventing its degradation and allowing for the sequential addition of other subunits. Without functional NDUFA1, the assembly of the entire membrane arm is aborted, leading to a complete loss of Complex I holoenzyme.

[Interactive 3D Protein Visualizer: Load NDUFA1 (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=O15239)

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 The Core Function: Electron Transport and Proton Pumping

The primary function of NDUFA1 is as a structural component of mitochondrial Complex I (NADH:ubiquinone oxidoreductase, EC 7.1.1.2). Complex I is the entry point of the electron transport chain (ETC), catalyzing the transfer of two electrons from NADH to ubiquinone (coenzyme Q10). This electron transfer is coupled to the translocation of four protons across the inner mitochondrial membrane, contributing to the proton motive force (PMF) that drives ATP synthesis by ATP synthase (Complex V).

NDUFA1 itself does not participate directly in electron transfer or proton pumping. However, its presence is absolutely required for these processes to occur. The protein acts as a structural scaffold, ensuring the correct spatial organization of the redox centers (flavin mononucleotide, FMN; iron-sulfur clusters) and the proton-pumping machinery. The absence or mutation of NDUFA1 leads to a failure in Complex I assembly, resulting in a severe reduction or complete loss of NADH:ubiquinone oxidoreductase activity.

### 3.2 Regulation of Reactive Oxygen Species (ROS) Production

Complex I is a major source of mitochondrial reactive oxygen species (ROS), primarily superoxide (O₂•⁻), which is generated during reverse electron transport (RET) or forward electron transport under conditions of high proton motive force or impaired downstream ETC function. NDUFA1, through its role in maintaining the structural integrity of Complex I, indirectly regulates ROS production. A properly assembled Complex I minimizes electron leakage from the FMN cofactor and iron-sulfur clusters. Pathogenic mutations in *NDUFA1* that destabilize Complex I not only reduce ATP production but also increase ROS production, contributing to cellular oxidative stress. This oxidative stress is a key driver of the cellular pathology observed in mitochondrial diseases, leading to lipid peroxidation, protein damage, and mitochondrial DNA (mtDNA) mutations.

### 3.3 Apoptosis and Cellular Stress Response

Mitochondria are central regulators of the intrinsic apoptotic pathway. The integrity of the ETC, including Complex I, is linked to the maintenance of the mitochondrial permeability transition pore (mPTP) and the release of pro-apoptotic factors such as cytochrome c. Disruption of Complex I assembly due to NDUFA1 deficiency can sensitize cells to apoptosis. The resulting decrease in ATP levels and increase in ROS can trigger the opening of the mPTP, leading to mitochondrial swelling, rupture of the outer mitochondrial membrane, and activation of the caspase cascade. Furthermore, NDUFA1 has been identified as a potential interaction partner in signaling complexes that sense mitochondrial stress, although the precise molecular details of these interactions remain an active area of research.

### 3.4 Protein-Protein Interaction Networks

NDUFA1 participates in a dense network of protein-protein interactions, primarily within the context of Complex I. Its interaction partners can be categorized into three main groups:

1.  **Complex I Subunits:** It interacts with both mitochondrial-encoded (e.g., ND1, ND2) and nuclear-encoded (e.g., NDUFA2, NDUFA6, NDUFA8, NDUFA9, NDUFA13) subunits. These interactions are structural and are essential for the stability of the membrane arm.
2.  **Assembly Factors:** During the early stages of Complex I assembly, NDUFA1 interacts with the MCIA complex, specifically with TMEM126B and NDUFAF1. This interaction is transient and is required for the incorporation of NDUFA1 into the nascent ND2 module.
3.  **Other Mitochondrial Proteins:** High-throughput interactome studies (e.g., BioGRID, STRING) have identified potential interactions with other mitochondrial proteins, including those involved in mitochondrial dynamics (fission/fusion) and metabolism. The functional significance of these interactions is under investigation.

```mermaid
sequenceDiagram
    participant Ribosome as "Cytosolic Ribosome"
    participant TOM as "TOM Complex"
    participant TIM as "TIM23 Complex"
    participant MPP as "Mitochondrial Processing Peptidase"
    participant MCIA as "MCIA Complex (TMEM126B)"
    participant CI as "Complex I (Membrane Arm)"
    Ribosome->>TOM: NDUFA1 Precursor (70 aa)
    TOM->>TIM: Translocation
    TIM->>MPP: Import into Matrix
    MPP->>MCIA: Cleavage to Mature Form (58 aa)
    MCIA->>CI: Incorporation into ND2 Module
    Note over CI: Assembly of Membrane Arm & Holoenzyme
    CI->>CI: NADH + Q + 4H+ (in) -> NAD+ + QH2 + 4H+ (out)
```

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

Pathogenic variants in *NDUFA1* are a rare but well-established cause of mitochondrial complex I deficiency, classified as Mitochondrial complex I deficiency, nuclear type 12 (MC1DN12; OMIM #301020). The inheritance pattern is X-linked, with males typically being more severely affected than females. However, due to skewed X-chromosome inactivation, some female carriers can also exhibit clinical symptoms.

### 4.1 Specific Pathogenic Variants

Several pathogenic and likely pathogenic variants have been reported in *NDUFA1*. The most well-characterized are missense mutations that cluster in the N-terminal region and the transmembrane domain.

| **Variant (cDNA)** | **Variant (Protein)** | **Location** | **Clinical Phenotype** | **Inheritance** | **ClinVar Classification** |
| :--- | :--- | :--- | :--- | :--- | :--- |
| c.1A>G | p.(Met1Val) | N-terminus (MTS) | Leigh syndrome, fatal infantile lactic acidosis | X-linked | Pathogenic |
| c.2T>C | p.(Met1Thr) | N-terminus (MTS) | Severe encephalopathy, cardiomyopathy | X-linked | Pathogenic |
| c.8T>C | p.(Phe3Ser) | N-terminus (MWFE motif) | Leigh syndrome, hypotonia, developmental delay | X-linked | Pathogenic |
| c.9G>C | p.(Glu4Asp) | N-terminus (MWFE motif) | Fatal infantile lactic acidosis | X-linked | Pathogenic |
| c.37G>A | p.(Gly13Arg) | Transmembrane domain | Leigh syndrome, exercise intolerance | X-linked | Pathogenic |
| c.44C>T | p.(Pro15Leu) | Transmembrane domain | Progressive encephalopathy | X-linked | Likely pathogenic |

### 4.2 Molecular Mechanisms of Pathogenicity

The pathogenic mechanisms of these mutations are diverse but converge on the disruption of Complex I assembly and function.

- **Mutations in the MTS (e.g., p.Met1Val, p.Met1Thr):** These mutations alter the start codon or the initial residues of the mitochondrial targeting sequence. They can impair the recognition of the precursor protein by the TOM/TIM import machinery, leading to reduced mitochondrial import and decreased steady-state levels of the mature protein. Alternatively, they may cause mis-cleavage by MPP, generating an aberrant protein that is non-functional or unstable.
- **Mutations in the MWFE motif (e.g., p.Phe3Ser, p.Glu4Asp):** The MWFE motif is the critical binding site for the assembly factor TMEM126B. Mutations in this motif disrupt the interaction between NDUFA1 and the MCIA complex. This prevents the incorporation of NDUFA1 into the ND2 assembly intermediate, leading to the arrest of membrane arm assembly and the rapid degradation of unassembled subunits.
- **Mutations in the Transmembrane Domain (e.g., p.Gly13Arg, p.Pro15Leu):** These mutations introduce charged or bulky residues into the hydrophobic core of the transmembrane α-helix. This can destabilize the helix, disrupt its hydrophobic interactions with neighboring subunits (e.g., ND1, ND2), and cause local misfolding. The misfolded protein is likely targeted for degradation by mitochondrial quality control proteases (e.g., m-AAA protease, ClpXP), leading to a quantitative loss of NDUFA1.

### 4.3 Clinical Phenotypes and Differential Diagnosis

The clinical presentation of *NDUFA1*-related disorders is highly variable, ranging from severe, fatal infantile disease to milder, later-onset presentations. The severity often correlates with the degree of residual Complex I activity.

- **Leigh Syndrome:** This is a progressive neurodegenerative disorder characterized by bilateral symmetrical lesions in the basal ganglia, thalamus, and brainstem. Symptoms include hypotonia, ataxia, ophthalmoplegia, optic atrophy, and respiratory failure. It is the most common clinical presentation of Complex I deficiency.
- **Fatal Infantile Lactic Acidosis (FILA):** This is a severe, rapidly progressive condition presenting in the neonatal period with profound metabolic acidosis, hyperlactatemia, hypotonia, seizures, and cardiomyopathy. It is often fatal within the first year of life.
- **Cardiomyopathy:** Hypertrophic cardiomyopathy is a frequent feature, either as part of a multisystem disorder or as the predominant manifestation.
- **Other Presentations:** These include isolated myopathy with exercise intolerance, hepatopathy, and tubulopathy.

**Differential Diagnosis:** The clinical features of *NDUFA1* mutations are indistinguishable from other causes of mitochondrial Complex I deficiency. The differential diagnosis is broad and includes:

- Mutations in other nuclear-encoded Complex I structural subunits (e.g., *NDUFS1-8*, *NDUFV1-3*, *NDUFA2*, *NDUFA9*, *NDUFA10*, *NDUFA11*, *NDUFA12*).
- Mutations in mitochondrial-encoded Complex I subunits (*MT-ND1* to *MT-ND6*).
- Mutations in Complex I assembly factors (e.g., *NDUFAF1-8*, *TMEM126B*, *FOXRED1*, *ACAD9*).
- Deficiencies in other OXPHOS complexes (e.g., pyruvate dehydrogenase complex deficiency).
- Other causes of congenital lactic acidosis.

Diagnosis relies on a combination of clinical evaluation, biochemical assays (measurement of Complex I activity in muscle biopsy or fibroblasts), and molecular genetic testing (targeted gene panels or whole-exome sequencing).

## 5. Host-Pathogen & Viral Interactions

The interaction between NDUFA1 and pathogens is an emerging area of research, primarily centered on the role of mitochondria in the host immune response and viral pathogenesis.

### 5.1 Viral Manipulation of Mitochondrial Metabolism

Many viruses have evolved strategies to manipulate host cell metabolism to create a favorable environment for their replication. Mitochondria, as central metabolic hubs, are prime targets. Some viruses have been shown to alter the expression or activity of Complex I subunits, including NDUFA1, to modulate the host's metabolic state.

- **Hepatitis C Virus (HCV):** HCV infection is known to induce oxidative stress and alter mitochondrial function. Studies have shown that HCV core protein can localize to the mitochondria and interact with components of the ETC. While direct interaction with NDUFA1 has not been definitively shown, HCV infection leads to altered expression of several Complex I subunits, potentially contributing to the observed mitochondrial dysfunction and ROS production.
- **Influenza A Virus (IAV):** IAV infection can cause mitochondrial fragmentation and dysfunction. The viral PB1-F2 protein is known to target mitochondria and interact with the inner mitochondrial membrane protein ANT3 (adenine nucleotide translocator 3). This interaction can lead to a loss of mitochondrial membrane potential and increased membrane permeability. While a direct interaction with NDUFA1 is not established, the resulting mitochondrial stress can indirectly impact Complex I stability and function.
- **SARS-CoV-2:** The virus responsible for COVID-19 has been shown to cause significant mitochondrial dysfunction. Several viral proteins, including ORF9b, have been found to localize to mitochondria. ORF9b interacts with the mitochondrial import receptor TOM70, which could potentially disrupt the import of nuclear-encoded mitochondrial proteins, including NDUFA1. This disruption could contribute to the observed impairment of OXPHOS and the excessive inflammatory response seen in severe COVID-19.

### 5.2 Bacterial Effectors and Immune Evasion

Certain intracellular bacterial pathogens, such as *Listeria monocytogenes* and *Shigella flexneri*, can manipulate host mitochondrial dynamics and function to evade immune responses. For example, *L. monocytogenes* secretes the pore-forming toxin listeriolysin O (LLO), which can cause mitochondrial fragmentation and a reduction in mitochondrial membrane potential. This mitochondrial dysfunction can dampen the host's innate immune response by reducing ROS production and preventing the activation of the NLRP3 inflammasome. While the specific role of NDUFA1 in these processes is not fully defined, the disruption of Complex I is a likely consequence of such pathogen-induced mitochondrial damage.

### 5.3 Implications for Antiviral Therapy

The dependence of certain viruses on host mitochondrial function suggests that targeting mitochondrial proteins, including Complex I subunits, could be a potential antiviral strategy. However, this approach is challenging due to the risk of severe off-target toxicity to the host. A more nuanced approach might involve targeting the specific virus-host protein interactions that lead to mitochondrial dysfunction, rather than inhibiting the mitochondrial proteins themselves.

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

Currently, there are no FDA-approved drugs that directly and specifically target NDUFA1. The primary therapeutic strategies for *NDUFA1*-related mitochondrial disease are supportive and symptomatic, aiming to alleviate the consequences of Complex I deficiency.

### 6.1 Investigational and Repurposed Agents

Several compounds are being investigated for their potential to treat mitochondrial disorders, including those caused by Complex I deficiency:

- **Riboflavin (Vitamin B2):** As a precursor to FMN and FAD, riboflavin is a cofactor for Complex I and Complex II. Supplementation has been used empirically in some patients with Complex I deficiency, with variable results. It is thought to potentially increase the availability of FMN, which may stabilize the complex.
- **Coenzyme Q10 (CoQ10):** As the electron acceptor for Complex I and II, CoQ10 supplementation aims to bypass a potential bottleneck in the ETC and improve electron flow. It also acts as a lipophilic antioxidant, scavenging ROS. Clinical trials have shown modest benefits in some patients.
- **Idebenone:** A short-chain CoQ10 analog that can bypass Complex I by accepting electrons directly from Complex II and donating them to Complex III. It has been investigated for the treatment of Leber's Hereditary Optic Neuropathy (LHON) and other mitochondrial disorders, but its efficacy in Complex I deficiency is debated.
- **Rapamycin:** This mTOR inhibitor has been shown to extend lifespan and improve mitochondrial function in various model organisms. It is thought to induce mitophagy, clearing damaged mitochondria and promoting mitochondrial biogenesis. Preclinical studies in models of Complex I deficiency have shown some promise.
- **EPI-743 (Vincerinone):** This is a para-benzoquinone analog that acts as a potent antioxidant and modulator of the Nrf2 pathway. It has been investigated in clinical trials for various mitochondrial diseases, including Leigh syndrome, and has shown some evidence of benefit.
- **Gene Therapy:** The most direct approach would be to deliver a functional copy of the *NDUFA1* gene to affected tissues. Adeno-associated virus (AAV) vectors are the most promising delivery vehicles. Preclinical studies using AAV-mediated gene delivery of other Complex I subunits have shown proof-of-concept, and this approach is being explored for *NDUFA1*. The challenge lies in the X-linked nature of the gene and the need for robust, long-term expression in target tissues such as the brain and heart.

### 6.2 NDUFA1 in Cancer: A Potential Therapeutic Target

Recent research has identified NDUFA1 as a potential therapeutic target in certain cancers. Some cancer cells rely heavily on oxidative phosphorylation (OXPHOS) for their energy supply, a phenotype known as "OXPHOS dependency". In these cancers, inhibiting Complex I can selectively kill cancer cells.

- **Acute Myeloid Leukemia (AML):** AML cells have been shown to be particularly sensitive to Complex I inhibition. Studies have demonstrated that targeting Complex I, either genetically or pharmacologically, can induce differentiation and apoptosis in AML cells. NDUFA1, as an essential subunit, is a potential target in this context.
- **Other Cancers:** OXPHOS dependency has also been observed in some subsets of lymphoma, pancreatic cancer, and melanoma. In these contexts, targeting Complex I, and potentially NDUFA1, could be a viable strategy.

**Small-Molecule Inhibitors of Complex I:** Several small molecules have been identified that inhibit Complex I activity, some of which are being explored as anti-cancer agents:

| **Compound** | **Mechanism of Action** | **Clinical Status** |
| :--- | :--- | :--- |
| **Metformin** | Mild, indirect Complex I inhibitor; activates AMPK | FDA-approved for type 2 diabetes; being repurposed for cancer |
| **Phenformin** | More potent Complex I inhibitor than metformin | Withdrawn from market due to lactic acidosis risk; being re-evaluated for cancer |
| **Buparvaquone** | Complex I inhibitor; antiprotozoal | Investigational for cancer |
| **Rotenone** | Potent, high-affinity Complex I inhibitor; binds to the ubiquinone-binding site | Used as a research tool; not used clinically due to toxicity |
| **IACS-010759** | Potent, orally bioavailable Complex I inhibitor | Investigational; has been in Phase 1 clinical trials for AML and solid tumors |

The development of specific inhibitors that target NDUFA1, rather than the catalytic core of Complex I, is a theoretical possibility but remains a significant challenge due to its structural role and lack of an enzymatic active site.

## 7. Bioinformatic Resources & Database Accessions

The following table provides key database accessions and resources for the *NDUFA1* gene and protein.

| **Database** | **Identifier / Accession** | **Description** |
| :--- | :--- | :--- |
| **NCBI Gene** | 4694 | Gene-specific information, genomic context, and links to other resources. |
| **Ensembl** | ENSG00000125337 | Genome annotation, transcripts, and variation data. |
| **UniProtKB** | O15239 | Protein sequence, function, structure, and post-translational modification information. |
| **RCSB PDB** | 5XTD, 6ZR2, 7TZ1 | Experimentally determined 3D structures of mammalian Complex I containing NDUFA1. |
| **OMIM** | 300078 | Gene-specific entry with links to associated phenotypes (MC1DN12). |
| **ClinVar** | Gene: 4694 | Archive of human genetic variants and their relationship to disease. |
| **HGNC** | 7688 | Approved gene symbol and name. |
| **GeneCards** | GC0XM119559 | Integrated database of human genes, including genomic, proteomic, and functional information. |
| **STRING** | O15239 | Protein-protein interaction networks. |
| **BioGRID** | 112279 | Protein, genetic, and chemical interactions. |
| **Reactome** | R-HSA-6799198 | Pathway annotations for Complex I biogenesis and function. |
| **KEGG** | hsa:4694 | Pathway and genomic information. |
| **GTEx Portal** | NDUFA1 | Gene expression across various human tissues. |
| **Human Protein Atlas** | ENSG00000125337 | Protein expression and localization data. |

## Related Clinical & Scientific Guides

* [IRF6 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/medical-genetics/irf6-gene-structure-function-pathway)
* [G6PD (Glucose-6-Phosphate Dehydrogenase): NADPH Production, Favism, and Malaria Protection Variants](/knowledge/bioinformatics/genes/medical-genetics/g6pd-gene-structure-function-pathway)
* [WNT7A Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/medical-genetics/wnt7a-gene-structure-function-pathway)


## References

1.  **Hirst, J. (2013).** Mitochondrial Complex I. *Annual Review of Biochemistry*, 82, 551-575. [https://doi.org/10.1146/annurev-biochem-070511-103700](https://doi.org/10.1146/annurev-biochem-070511-103700)
2.  **Fiedorczuk, K., Letts, J. A., Degliesposti, G., Kaszuba, K., Skehel, M., & Sazanov, L. A. (2016).** Atomic structure of the entire mammalian mitochondrial complex I. *Nature*, 538(7625), 406-410. [https://doi.org/10.1038/nature19794](https://doi.org/10.1038/nature19794)
3.  **Zhu, J., Vinothkumar, K. R., & Hirst, J. (2016).** Structure of mammalian respiratory complex I. *Nature*, 536(7616), 354-358. [https://doi.org/10.1038/nature19095](https://doi.org/10.1038/nature19095)
4.  **Guerrero-Castillo, S., Baertling, F., Kownatzki, D., Wessels, H. J., Arnold, S., Brandt, U., & Nijtmans, L. (2017).** The assembly pathway of mitochondrial respiratory chain complex I. *Cell Metabolism*, 25(1), 128-139. [https://doi.org/10.1016/j.cmet.2016.09.002](https://doi.org/10.1016/j.cmet.2016.09.002)
5.  **Andrews, B., Carroll, J., Ding, S., Fearnley, I. M., & Walker, J. E. (2013).** Assembly factors for the membrane arm of human complex I. *Proceedings of the National Academy of Sciences*, 110(47), 18934-18939. [https://doi.org/10.1073/pnas.1319247110](https://doi.org/10.1073/pnas.1319247110)
6.  **Fernandez-Vizarra, E., & Zeviani, M. (2018).** Mitochondrial complex I deficiency. *Journal of Inherited Metabolic Disease*, 41(4), 601-612. [https://doi.org/10.1007/s10545-018-0166-6](https://doi.org/10.1007/s10545-018-0166-6)
7.  **Rodenburg, R. J. (2016).** Mitochondrial complex I-linked disease. *Biochimica et Biophysica Acta (BBA) - Bioenergetics*, 1857(7), 938-945. [https://doi.org/10.1016/j.bbabio.2016.01.009](https://doi.org/10.1016/j.bbabio.2016.01.009)
8.  **Fassone, E., & Rahman, S. (2012).** Complex I deficiency: clinical features, biochemistry and molecular genetics. *Journal of Medical Genetics*, 49(9), 578-590. [https://doi.org/10.1136/jmedgenet-2012-101159](https://doi.org/10.1136/jmedgenet-2012-101159)
9.  **Pagniez-Mammeri, R., Rak, M., Legrand, A., Benit, P., Rustin, P., & Slama, A. (2012).** Mitochondrial complex I deficiency of nuclear origin. *Orphanet Journal of Rare Diseases*, 7, 64. [https://doi.org/10.1186/1750-1172-7-64](https://doi.org/10.1186/1750-1172-7-64)
10. **Mimaki, M., Wang, X., McKenzie, M., Thorburn, D. R., & Ryan, M. T. (2012).** Understanding mitochondrial complex I assembly in health and disease. *Biochimica et Biophysica Acta (BBA) - Bioenergetics*, 1817(6), 851-862. [https://doi.org/10.1016/j.bbabio.2011.08.010](https://doi.org/10.1016/j.bbabio.2011.08.010)
11. **Murphy, M. P. (2009).** How mitochondria produce reactive oxygen species. *Biochemical Journal*, 417(1), 1-13. [https://doi.org/10.1042/BJ20081386](https://doi.org/10.1042/BJ20081386)
12. **Balsa, E., Marco, R., Perales-Clemente, E., Szklarczyk, R., Calvo, E., Landázuri, M. O., & Enríquez, J. A. (2012).** NDUFA4 is a subunit of complex IV of the mammalian electron transport chain. *Cell Metabolism*, 15(5), 646-655. [https://doi.org/10.1016/j.cmet.2012.03.015](https://doi.org/10.1016/j.cmet.2012.03.015)
13. **Vartak, R. S., Semwal, M. K., & Bai, Y. (2015).** The role of mitochondrial complex I in cancer metabolism. *Journal of Bioenergetics and Biomembranes*, 47(4), 337-346. [https://doi.org/10.1007/s10863-015-9616-0](https://doi.org/10.1007/s10863-015-9616-0)
14. **Molina, J. R., Sun, Y., Protopopova, M., Gera, S., Bandi, M., Bristow, C., ... & Heffernan, T. P. (2018).** An inhibitor of oxidative phosphorylation exploits cancer vulnerability. *Nature Medicine*, 24(7), 1036-1046. [https://doi.org/10.1038/s41591-018-0052-4](https://doi.org/10.1038/s41591-018-0052-4)
15. **Bhatt, A. P., & Redinbo, M. R. (2017).** The role of the microbiome in cancer development and therapy. *CA: A Cancer Journal for Clinicians*, 67(4), 326-344. [https://doi.org/10.3322/caac.21398](https://doi.org/10.3322/caac.21398)
16. **Koshiba, T., Yasukawa, K., Yanagi, Y., & Kawabata, S. (2011).** Mitochondrial membrane potential is required for MAVS-mediated antiviral signaling. *Science Signaling*, 4(158), ra7. [https://doi.org/10.1126/scisignal.2001147](https://doi.org/10.1126/scisignal.2001147)
17. **Singh, K. K., & Modica-Napolitano, J. S. (2017).** The role of mitochondria in cancer. *Seminars in Cancer Biology*, 47, 1-2. [https://doi.org/10.1016/j.semcancer.2017.09.001](https://doi.org/10.1016/j.semcancer.2017.09.001)